|
Volumn 148, Issue 6, 2012, Pages 1081-1084
|
Antibody-based immunotherapy of cancer
|
Author keywords
[No Author keywords available]
|
Indexed keywords
4 1BB AGONIST ANTIBODY;
ANGIOGENESIS INHIBITOR;
ANTIBODY CONJUGATE;
BISPECIFIC ANTIBODY;
BISPECIFIC T LYMPHOCYTE ENGAGER ANTIBODY;
BL 22;
BRENTUXIMAB VEDOTIN;
CAPECITABINE;
CATUMAXOMAB;
CETUXIMAB;
CVX 241;
DACARBAZINE;
ERTUMAXOMAB;
FC RECEPTOR;
IBRITUMOMAB TIUXETAN;
IMMUNOGLOBULIN G ANTIBODY;
IMMUNOGLOBULIN G1 ANTIBODY;
IMMUNOTOXIN;
IPH 2101;
IPILIMUMAB;
IRINOTECAN;
LAPATINIB;
MDX 1106;
MEHD 7945A;
MM 111;
MONOCLONAL ANTIBODY;
OX40 AGONIST ANTIBODY;
PANITUMUMAB;
TRASTUZUMAB EMTANSINE;
TUMOR ANTIGEN;
UNCLASSIFIED DRUG;
ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY;
ANTIBODY DIRECTED ENZYME PRODRUG THERAPY;
ANTIBODY STRUCTURE;
ANTIGEN EXPRESSION;
ANTIGEN PRESENTING CELL;
ANTINEOPLASTIC ACTIVITY;
ASCITES;
BREAST CANCER;
CANCER IMMUNOTHERAPY;
CANCER SURVIVAL;
CELLULAR IMMUNITY;
CLEAR CELL CARCINOMA;
CYTOTOXIC T LYMPHOCYTE;
CYTOTOXICITY;
DENDRITIC CELL;
DRUG MECHANISM;
DRUG POTENTIATION;
DRUG TARGETING;
FOLLICULAR LYMPHOMA;
HAIRY CELL LEUKEMIA;
HODGKIN DISEASE;
HUMAN;
HUMORAL IMMUNITY;
KIDNEY CARCINOMA;
LARGE CELL LYMPHOMA;
LOW DRUG DOSE;
LYMPHOMA;
MACROPHAGE;
MALIGNANT ASCITES;
MALIGNANT NEOPLASTIC DISEASE;
MELANOMA;
METASTASIS;
NONHODGKIN LYMPHOMA;
NONHUMAN;
OVERALL SURVIVAL;
PRIORITY JOURNAL;
PROSTATE CANCER;
RADIOIMMUNOTHERAPY;
REVIEW;
T LYMPHOCYTE;
TREATMENT OUTCOME;
TUMOR MICROENVIRONMENT;
|
EID: 84858416256
PISSN: 00928674
EISSN: 10974172
Source Type: Journal
DOI: 10.1016/j.cell.2012.02.034 Document Type: Review |
Times cited : (236)
|
References (20)
|